YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

June 6, 2012 updated by: Astellas Pharma Inc
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Canberra, Australia
        • Department of Medical Oncology, The Canberra Hospital
      • Concord, Australia
        • Department of Medical Oncology, Concord Hospital Medical Centre
      • Herston, Australia
        • Division of Oncology Ward, Royal Brisbane Hospital
      • St Leonards, Australia
        • Department of Clinical Oncology, Royal North Shore Hospital
      • Sydney, Australia
        • Cancer Care Centre, St. George Hospital
      • Waratah, Australia
        • Department of Medical Oncology, Newcastle Mater Hospital
      • Wollongong, Australia
        • Southern Medical Day Care Centre
      • Woodville, Australia
        • Queen Elizabeth Hospital, Clinical Hematology & Oncology
  • Belgium
      • Bruxelles, Belgium
        • Cliniques Universitaires St-Luc, Service d'Urologie
      • Charleroi, Belgium
        • Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie
  • France
      • Angers, France
        • Centre Paul Papin
      • Creteil, France
        • Service d'Urologie, Hôpital Henri Mondor
      • Lyon, France
        • Pavillon V, Service d'Urologie et de transplatation, Hôpital Edouard Herriot
      • Paris, France
        • Service d' Urologie CHU, Hopital Bichat
  • Germany
      • Berlin, Germany
        • Krankenhause am Urban, Urologie Dieffenfachstr
      • Essen, Germany
        • Dept Urology University of Essen
      • Hannover, Germany
        • Urologische Klinik der MHH
      • Mannheim, Germany
        • Klinikum Mannheim Urology
  • Ireland
      • Dublin, Ireland
        • Mater Misericordiae Hospital
  • Netherlands
      • Utrecht, Netherlands
        • Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie
  • Poland
      • Krakow, Poland
        • Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie
      • Krakow, Poland
        • Oddzial Chemioterapii
      • Lodz, Poland
        • Klinika Chemioterapii AM
      • Opole, Poland
        • Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii
      • Tarnow, Poland
        • Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow
      • Warsaw, Poland
        • Szpital CSK WAMl, Klinika Okologii
      • Warszawa, Poland
        • Klinika Nowotworow Ukladu
  • Spain
      • Barcelona, Spain
        • Hospital Clinic i Provincial, Servicio de Oncologia
      • Barcelona, Spain
        • Hospital General Vall d'Hebron, Servicio de Oncología
      • Getafe (Madrid), Spain
        • Hospital Universitario de Getafe, Servicio de Urologia, Crta
      • Madrid, Spain
        • Hospital Universitario Príncipe de Asturias, Servicio de Urología
      • Valencia, Spain
        • Instituto Valenciano de Oncologia, Servicio de Oncologia
  • United Kingdom
      • Devon, United Kingdom
        • Department of Urological Research, Derriford Hospital
      • London, United Kingdom
        • Clinical Research Centre, St George's Hospital, Urology Division
      • London, United Kingdom
        • Department of Urology, St Bartholomew's Hospital
      • London, United Kingdom
        • Imperial College School of Medicine, Dept Cancer Medicine
      • Surrey, United Kingdom
        • Royal Surrey County Hospital
      • Surrey, United Kingdom
        • Department of Urology, East Surrey Hospital
      • West Sussex, United Kingdom
        • St Richard's Hospital
  • United States
    • Alaska
      • Anchorage, Alaska, United States
        • Alaska Clinical Research Center, LLC
    • California
      • San Bernardino, California, United States
        • San Bernardino Urological Associates
      • Torrance, California, United States
        • Western Clinical Research, Inc.
    • Florida
      • Gainesville, Florida, United States
        • Shands Hospital
      • Miami, Florida, United States
        • Sylvester Comprehensive Cancer Center
    • Georgia
      • Atlanta, Georgia, United States
        • Georgia Urology,PA Research Institute
    • Illinois
      • Chicago, Illinois, United States
        • University of Chicago, Section of Hematology/Oncology
      • Chicago, Illinois, United States
        • University of Illinois, Department of Urology
    • Indiana
      • South Bend, Indiana, United States
        • Michiana Hematology/Oncology
    • Louisiana
      • Gretna, Louisiana, United States
        • The Urologic Institute of New Orleans
    • Michigan
      • Detroit, Michigan, United States
        • Henry Ford Hospital
    • Missouri
      • St. Louis, Missouri, United States
        • Washington University School of Medicine
    • Tennessee
      • Memphis, Tennessee, United States
        • Memphis Cancer Center
    • Washington
      • Seattle, Washington, United States
        • Virginia Mason Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Astellas Pharma Inc

Collaborators

Astellas Pharma US, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Completion (Actual)

June 1, 2004

Study Registration Dates

First Submitted

November 4, 2002

First Submitted That Met QC Criteria

November 5, 2002

First Posted (Estimate)

November 6, 2002

Study Record Updates

Last Update Posted (Estimate)

June 7, 2012

Last Update Submitted That Met QC Criteria

June 6, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 598-CL-008

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostatic Neoplasms

Clinical Trials on YM598

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe